We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+6.61%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$1B
AUM Growth
+$47.9M
(+5%)
Cap. Flow
+$3.61M
Cap. Flow
% of AUM
0.36%
Top 10 Holdings %
Top 10 Hldgs %
53.49%
Holding
65
New
7
Increased
13
Reduced
12
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$12M |
| 2 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$10.2M |
| 3 |
Heron Therapeutics
HRTX
|
+$9.31M |
| 4 |
Viatris
VTRS
|
+$7.96M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$7.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$15.3M |
| 2 |
HOLX
Hologic
HOLX
|
+$9.94M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$8.51M |
| 4 |
Perrigo
PRGO
|
+$8.4M |
| 5 |
CELG
Celgene Corp
CELG
|
+$6.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.13% |
| 2 | Financials | 1.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$163B
| $107M | 10.66% |
1,504,712
| – | – |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $65.9M | 6.59% |
944,092
-76,000
| -7% | -$6.02M |
|
|
3
Regeneron Pharmaceuticals
REGN
$77.4B
| $63.4M | 6.34% |
211,166
-49,533
| -19% | -$15.3M |
|
4
Amgen
AMGN
$209B
| $55.4M | 5.54% |
449,543
+37,400
| +9% | +$4.54M |
|
5
Biogen
BIIB
$30.7B
| $53.2M | 5.32% |
173,983
-18,000
| -9% | -$5.71M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $51.1M | 5.11% |
335,899
-35,430
| -10% | -$5.63M |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $42.3M | 4.23% |
205,707
| – | – |
|
8
Vertex Pharmaceuticals
VRTX
$122B
| $35.3M | 3.53% |
499,764
| – | – |
|
|
9
Viatris
VTRS
$20.7B
| $31.8M | 3.18% |
652,209
+164,000
| +34% | +$7.96M |
|
10
Incyte
INCY
$24.9B
| $29.9M | 2.99% |
558,080
-30,220
| -5% | -$1.88M |
|
|
11
BioMarin Pharmaceuticals
BMRN
$11.7B
| $28.7M | 2.87% |
421,384
+163,143
| +63% | +$12M |
|
|
AGN
12
DELISTED
Allergan Inc
AGN
| $26.8M | 2.68% |
216,337
+49,760
| +30% | +$6.06M |
|
|
13
Perrigo
PRGO
$1.43B
| $26M | 2.6% |
167,874
-53,250
| -24% | -$8.4M |
|
|
14
iShares Biotechnology ETF
IBB
$9.52B
| $24.1M | 2.41% |
306,240
-102,078
| -25% | -$8.51M |
|
|
SHPG
15
DELISTED
Shire pic
SHPG
| $22.9M | 2.29% |
154,153
| – | – |
|
16
Puma Biotechnology
PBYI
$402M
| $19.4M | 1.93% |
185,820
| – | – |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $18.5M | 1.85% |
246,841
| – | – |
|
|
CBST
18
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $16.6M | 1.66% |
226,772
| – | – |
|
19
Teva Pharmaceuticals
TEVA
$41.2B
| $16.5M | 1.65% |
311,476
| – | – |
|
20
Illumina
ILMN
$31B
| $15.4M | 1.54% |
106,749
| – | – |
|
|
AKRX
21
DELISTED
Akorn Inc
AKRX
| $15.4M | 1.54% |
699,382
-236,376
| -25% | -$5.52M |
|
|
FRX
22
DELISTED
FOREST LABORATORIES INC
FRX
| $13.5M | 1.35% |
146,500
| – | – |
|
23
McKesson
MCK
$101B
| $12M | 1.2% |
67,862
+11,000
| +19% | +$1.92M |
|
|
CTRX
24
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $10.3M | 1.03% |
231,000
+85,000
| +58% | +$4.09M |
|
25
Verastem
VSTM
$536M
| $9.91M | 0.99% |
76,569
-8,333
| -10% | -$1.33M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2014 Portfolio in Review
As of Q1 2014, Tekla Capital Management held 65 positions worth $1B, up 5% from $952M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Tekla Capital Management's Q1 2014 filing shows 7 new, 13 increased, 12 reduced and 4 closed positions. Its largest new stake was Eiger BioPharmaceuticals, Inc.: 2,157 shares worth $9.83M. The largest sale was Regeneron Pharmaceuticals, an estimated $15.3M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Financials.
- Tekla Capital Management's largest Q1 2014 buy was Eiger BioPharmaceuticals, Inc.: 2,157 shares worth $9.83M.
- Tekla Capital Management added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $12M increase.
- Tekla Capital Management's biggest Q1 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $15.3M.
- Tekla Capital Management fully exited Hologic in Q1 2014, selling an estimated $9.94M.
- Tekla Capital Management's ten largest holdings make up 53% of its $1B portfolio in Q1 2014.
- Tekla Capital Management opened 7 new positions and closed 4 in Q1 2014.
- Tekla Capital Management's portfolio value rose 5% quarter-over-quarter to $1B.
Based on Tekla Capital Management's 13F filing for Q1 2014, filed 13 May 2014.